President Donald Trump received a dose of REGN-COV2 following an “expanded access” request from the president’s physicians.
REGN-COV2 is an investigational antibody cocktail that is in clinical trials for the treatment of COVID-19. It consists of two potent, complementary virus-neutralizing antibodies and was designed specifically to target the SARS-CoV-2 (COVID-19) virus.
Individuals interested in participating in Regeneron’s COVID-19 clinical trials can complete a screener at ClinLife.com/COVID to see if they qualify.
In Other News
1
5-year-old girl found safe after getting on wrong bus in Dayton
2
Holiday bazaars in November: Where to find unique gifts, treats
3
Regional business leaders list priorities for new Trump term
4
Mystery custom welder eyes Brookville (or Union) for $11.3 million...
5
Troy studies future plans for city water park, could add major feature
About the Author